InvestorsHub Logo
Followers 5
Posts 277
Boards Moderated 0
Alias Born 05/29/2011

Re: None

Saturday, 02/03/2018 12:21:47 PM

Saturday, February 03, 2018 12:21:47 PM

Post# of 3443
Article on TLR-9 eradicating tumors getting attention....


Good exposure for potential of TLR-9s in checkpoint combo immunotherapy. Study used Dynavax's SD-101 in combo with OX-40 mAb. Limited comparative data with IMO-2125, but in PD-1 R/R melanoma so far, IMO+ipi showing 50% ORR (5/10) versus 17% (2/12) for SD-101+pembro (100% ORR 7/7 for SD-101+pembro in PD-1 naive). Should see IMO+pembro data in PD-1 R/R soon to make meaningful comparison.

No pre-clinical of IMO+OX-40 to date, but proven synergy with other checkpoints, notably IDO1.


http://stm.sciencemag.org/content/10/426/eaan4488